If you suffer from knee pain due to a cartilage injury, you may be eligible for a study on new treatments.
This is a clinical investigation of the efficacy of GelrinC® (Regentis, Or-Akiva, Israel) augmented microfracture for the treatment of isolated cartilage lesions. The full terms of the investigation are detailed and disclosed in the patient consent form and will be described to patients by the physician or research coordinator upon inquiry. Eligible patients may be contact by either the physician or research coordinator prior to their scheduled surgery.
This clinical trial is a new approach to treatment of cartilage lesions with microfracture. To be eligible for this study, you must: